Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Rigosertib in Combination with Azacitidine Impacts Metabolic and Differentiation Pathways in the MDS-L Cell Line

Richa Rai, PhD, Foramben Patel, MS, Stella Melana, PhD, Jonathan Feld, MD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, E. Premkumar Reddy, PhD, Lewis R. Silverman, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-142908

Published: 2020

Journal Articles

Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic

Jonathan Feld, MD, Erin P. Demakos, RN, Rosalie Odchimar-Reissig, RN, Douglas Tremblay, MD, Saudia Alli, NP, Darshanie Sewah, RN, Shyamala C. Navada, MD, Lewis R. Silverman, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-138969

Published: 2020

Journal Articles

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Afoluso Ronnee Adesanya, MD, Patrick S. Zbyszewski, MBA, Richard C. Woodman, MD, Pierre Fenaux, MD PhD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 566.

https://doi.org/10.1182/blood-2019-131676

Published: 2019

Journal Articles

Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes (MDS)

Camille Bigenwald, MD, Amir Horowitz, PhD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Richa Rai, PhD, Stella Melana, PhD, Erin P. Demakos, RN, Miriam Merad, MD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 2986.

https://doi.org/10.1182/blood-2019-124887

Published: 2019

Journal Articles

T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous Immunoglobulin

Jonathan Feld, MD, Francesca Schieppati, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, Shyamala C. Navada, MD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 4260.

https://doi.org/10.1182/blood-2019-128656

Published: 2019

Journal Articles

The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/β-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome

Richa Rai, PhD, Stella Melana, PhD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, E. Premkumar Reddy, PhD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 4231.

https://doi.org/10.1182/blood-2019-130747

Published: 2019

Journal Articles

Sequential Treatment with Rigosertib Followed By Azacitidine Maximizes the Effects on the Interferon Signaling Pathway in Hematopoietic Cells in Myelodysplastic Syndrome (MDS)

Richa Rai, PhD, Stella Melana, PhD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, E. Premkumar Reddy, PhD, Lewis R. Silverman, MD

Blood (2018) 132 (Supplement 1): 5500.

https://doi.org/10.1182/blood-2018-99-119266

Published: 2018

Journal Articles

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Naveen Pemmaraju, MD, Yesid Alvarado, MD, Maro N. Ohanian, DO, Rosmy B. John, MSN, Patrick S. Zbyszewski, MBA, Manoj Maniar, PhD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2018) 132 (Supplement 1): 230.

https://doi.org/10.1182/blood-2018-99-119259

Published: 2018

Journal Articles

Effects of Rigosertib (RIGO) Alone or in Combination with Azacitidine or Vorinostat on Epigenetic Reprogramming of CD34+ Cells in the Myelodysplastic Syndrome

Lewis R Silverman, MD, Pratima Chaurasia, PhD, Stella Melana, PhD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, BA, BSN, MSN, RN, Shyamala C. Navada, MD, E. Premkumar Reddy, PhD BSc, MSc

Blood (2017) 130 (Supplement 1): 4235.

https://doi.org/10.1182/blood.V130.Suppl_1.4235.4235

Published: 2017

Journal Articles

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Katherine P. Hearn, BSN, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney D DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Pierre Fenaux, MD PhD, Michael E. Petrone, MD MPH, Patrick Simon Zbyszewski, MBA, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2016) 128 (22): 3167.

https://doi.org/10.1182/blood.V128.22.3167.3167

Published: 2016

Journal Articles

A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)

Shyamala C. Navada, MD, Lewis R. Silverman, MD, Katherine P. Hearn, BSN, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Tapan Kadia, MD, Pierre Fenaux, MD PhD, Steve Fruchtman, MD, Nozar Azarnia, PhD, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 910.

https://doi.org/10.1182/blood.V126.23.910.910

Published: 2015

Journal Articles

A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Francois Wilhelm, MD PhD, Katherine Hearn, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney D. DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Nozar Azarnia, PhD, Lewis R. Silverman, MD

Blood (2014) 124 (21): 3252.

https://doi.org/10.1182/blood.V124.21.3252.3252

Published: 2014

Journal Articles

Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents

Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, E. Premkumar Reddy, PhD, Erin P Demakos, RN, CCRN, James F Holland, MD, Francois Wilhelm, MD, PhD., Lewis R. Silverman, MD

Blood (2013) 122 (21): 1527.

https://doi.org/10.1182/blood.V122.21.1527.1527

Published: 2013

Journal Articles

A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination With Azacitidine (azaC) In Patients With The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium

Lewis R. Silverman, MD, Amit Verma, MD, Rosalie Odchimar-Reissig, RN, Eric J. Feldman, MD, Shyamala C. Navada, MD, Erin P Demakos, RN, Maria R. Baer, MD, Vesna Najfeld, PhD, Joseph A Sparano, MD, Richard Piekarz, MD, PhD

Blood (2013) 122 (21): 386.

https://doi.org/10.1182/blood.V122.21.386.386

Published: 2013

Journal Articles

Dose Escalation of Azacitidine in Patients Failing Standard or Investigational Combinations of the Agent in the Myelodysplastiic Syndrome or Evolved AML

Lewis R. Silverman, MD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Maria Michalak, PA-C, Erin P Demakos, RN, CCRN, James F Holland, MD

Blood (2012) 120 (21): 4932.

https://doi.org/10.1182/blood.V120.21.4932.4932

Published: 2012

Journal Articles

Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study

Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, E. Premkumar Reddy, PhD, James F Holland, MD, Francois Wilhelm, MD, PhD., Lewis R. Silverman, MD

Blood (2012) 120 (21): 3794.

https://doi.org/10.1182/blood.V120.21.3794.3794

Published: 2012

Journal Articles

Evaluation of ON01910.Na In Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study

Lewis R Silverman, MD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Vesna Najfeld, PhD, Takao Ohnuma, MD, Francois Wilhelm, MD, PhD., E. Premkumar Reddy, Ph.D., James F. Holland, MD

Blood (2010) 116 (21): 2944.

https://doi.org/10.1182/blood.V116.21.2944.2944

Published: 2010

Journal Articles

Eradication and Reduction of the Abnormal Chromosome 7 Clone with Azacitidine (AZA C) Is Achievable for One-Third of Patients (pts) with Myelodysplastic Syndrome (MDS).

Vesna Najfeld, PhD, Angela Scalise, BA, Rosalie Odchimar-Reissig, RN, Lewis R. Silverman, M.D.

Blood (2007) 110 (11): 5181.

https://doi.org/10.1182/blood.V110.11.5181.5181

Published: 2007

Journal Articles

Rates of Infection and Bleeding Are Not Increased in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine Compared with Supportive Care.

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Rosalie Odchimar-Reissig, RN, MSN, CCRC, Randy Hinkle, RPh, Jay T. Backstrom, MD, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB).

Blood (2005) 106 (11): 2525.

https://doi.org/10.1182/blood.V106.11.2525.2525

Published: 2005

NARROW

Rigosertib in Combination with Azacitidine Impacts Metabolic and Differentiation Pathways in the MDS-L Cell Line

Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes (MDS)

T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous Immunoglobulin

The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/β-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome

Sequential Treatment with Rigosertib Followed By Azacitidine Maximizes the Effects on the Interferon Signaling Pathway in Hematopoietic Cells in Myelodysplastic Syndrome (MDS)

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Effects of Rigosertib (RIGO) Alone or in Combination with Azacitidine or Vorinostat on Epigenetic Reprogramming of CD34+ Cells in the Myelodysplastic Syndrome

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study

A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)

A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents

A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination With Azacitidine (azaC) In Patients With The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium

Dose Escalation of Azacitidine in Patients Failing Standard or Investigational Combinations of the Agent in the Myelodysplastiic Syndrome or Evolved AML

Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study

Evaluation of ON01910.Na In Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study

Eradication and Reduction of the Abnormal Chromosome 7 Clone with Azacitidine (AZA C) Is Achievable for One-Third of Patients (pts) with Myelodysplastic Syndrome (MDS).

Rates of Infection and Bleeding Are Not Increased in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine Compared with Supportive Care.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only